MS Treatment and Gut Health: What New Research Found

Credibility

Interest

Share:2 min read

Key Takeaway

In a Swedish study, people with MS taking rituximab were more likely to develop inflammatory bowel disease than those taking three other MS treatments, though the overall risk was low.

What They Found

Researchers followed Swedish adults with relapsing MS, a form in which symptoms flare up and then ease, who started one of four treatments. Inflammatory bowel disease, or IBD, means long-lasting swelling in the gut that can cause problems such as diarrhea and belly pain. Among 6,481 periods of rituximab treatment, researchers found 40 new IBD cases, compared with four cases across 7,267 periods of treatment with natalizumab, dimethyl fumarate, or fingolimod. After accounting for differences between the groups, they estimated that treating 131 people with rituximab instead of those other medicines for five years would lead to one additional IBD case. Most IBD cases in the rituximab group were Crohn disease, a type of IBD that can affect different parts of the digestive tract.

Who Should Care and Why

If you take rituximab for MS, this finding gives you one more health issue to discuss with your care team, not a reason to stop treatment on your own. Tell your clinician about ongoing diarrhea, belly pain, or blood in your stool so they can check what is causing it. If you are choosing an MS treatment, ask how its benefits for your MS compare with its possible risks, including gut problems. Caregivers can help by noticing symptoms that keep coming back and helping the person with MS report them. Healthcare providers can use these findings to discuss treatment choices and take new gut symptoms seriously.

Important Considerations

This study found a link between rituximab and IBD, but it cannot prove the medicine caused each case. It studied Swedish adults ages 18 to 55 with relapsing MS, so the results may not apply in the same way to everyone with MS. Only four IBD cases occurred in the other treatment groups combined, which makes that comparison less certain.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Nutrition Caregivers

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News